Volume 74, Issue 4, Pages (October 2018)

Slides:



Advertisements
Similar presentations
Volume 70, Issue 3, Pages (September 2016)
Advertisements

Volume 59, Issue 2, Pages (February 2011)
The PSA Era is not Over for Prostate Cancer
Volume 70, Issue 5, Pages (November 2016)
Improving Quality of Life (QoL) in Hormonal Therapy (ADT)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Testosterone Therapy in Men With Prostate Cancer
Volume 69, Issue 5, Pages (May 2016)
Volume 61, Issue 6, Pages (June 2012)
Volume 53, Issue 4, Pages (April 2008)
Prostate Cancer: Highlights from 2006
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A
Volume 66, Issue 4, Pages (October 2014)
Volume 70, Issue 4, Pages (October 2016)
Volume 53, Issue 5, Pages (May 2008)
Control of Prostate Cancer by Transrectal HIFU in 227 Patients
Volume 69, Issue 1, Pages (January 2016)
Volume 69, Issue 5, Pages (May 2016)
Volume 69, Issue 1, Pages (January 2016)
Volume 53, Issue 5, Pages (May 2008)
Hormone Therapy for Prostate Cancer: Exploring Current Controversies
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Volume 49, Issue 5, Pages (May 2006)
Volume 62, Issue 6, Pages (December 2012)
Volume 59, Issue 2, Pages (February 2011)
Volume 50, Issue 4, Pages (October 2006)
Volume 68, Issue 4, Pages (October 2015)
Volume 71, Issue 1, Pages 1-3 (January 2017)
What is New in Hormone Therapy for Prostate Cancer in 2007?
Volume 60, Issue 4, Pages (October 2011)
Volume 68, Issue 4, Pages (October 2015)
Laurent Boccon-Gibod  European Urology Supplements 
Volume 68, Issue 3, Pages (September 2015)
The PSA Era is not Over for Prostate Cancer
Yuanshan Cui, Yong Zhang  European Urology 
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 61, Issue 6, Pages (June 2012)
Volume 58, Issue 4, Pages (October 2010)
Volume 74, Issue 2, Pages (August 2018)
Volume 53, Issue 4, Pages (April 2008)
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer  Matthew R. Smith  European Urology Supplements 
Volume 73, Issue 2, Pages (February 2018)
Volume 50, Issue 3, Pages (September 2006)
Volume 50, Issue 5, Pages (November 2006)
Volume 55, Issue 3, Pages (March 2009)
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Volume 71, Issue 3, Pages (March 2017)
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis
Jacques Irani  European Urology Supplements 
Neal Shore  European Urology Supplements 
Volume 49, Issue 4, Pages (April 2006)
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer  Amar U. Kishan, Rahul.
Volume 72, Issue 2, Pages (August 2017)
Long-Term Hormonal Therapy: Who Would Benefit?
Volume 75, Issue 3, Pages (March 2019)
New Trends in Managing the Prostate Cancer Patient
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results.
Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis  Joseph Sargon Joseph, Vincent.
Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.
Axel Heidenreich  European Urology Supplements 
Improving Flexibility and Quality of Life for Your Patients: A Must?
Volume 53, Issue 6, Pages (June 2008)
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis  Sarah Burdett, Liselotte M. Boevé,
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Physical Function in Patients with Cancer
Axel Heidenreich  European Urology Supplements 
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 74, Issue 4, Pages 432-441 (October 2018) Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial  Abdenour Nabid, Nathalie Carrier, André-Guy Martin, Jean-Paul Bahary, Céline Lemaire, Sylvie Vass, Boris Bahoric, Robert Archambault, François Vincent, Redouane Bettahar, Marie Duclos, Marie-Pierre Garant, Luis Souhami  European Urology  Volume 74, Issue 4, Pages 432-441 (October 2018) DOI: 10.1016/j.eururo.2018.06.018 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Enrollment and follow-up of study patients. AA=anti-androgen; ADT=androgen deprivation therapy; Gy=Gray; LHRHa=luteinizing hormone-releasing hormone agonist; RT=radiotherapy. European Urology 2018 74, 432-441DOI: (10.1016/j.eururo.2018.06.018) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Survival and biochemical failure rates between long arm (36 mo) and short arm (18 mo). HR=hazard ratio with 95% confidence intervals. HR compared between 36 mo and 18 mo. European Urology 2018 74, 432-441DOI: (10.1016/j.eururo.2018.06.018) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Mean scores on quality of life assessment scales or items and time to normal testosterone level recovery. The mean scores were presented for global quality of life (A) (0 indicate no QoL and 100 high QoL), and sexual activity (B) (0 indicate no sexual activity and 100 high sexual activity). Other items: (C) interest in sex (0 indicate no interest and 100 high interest), (D) hot flushes (0 indicate no symptoms and 100 severe symptoms), (E) enjoyable sex (0 indicate no enjoyable and 100 high enjoyable). (F) Time to normal testosterone recovery. A p value<0.01 was considered statistically significant to account for multiple comparisons and a difference between groups in mean scores of ≥10 points as clinically relevant. CI=confidence interval; QoL=quality of life. European Urology 2018 74, 432-441DOI: (10.1016/j.eururo.2018.06.018) Copyright © 2018 European Association of Urology Terms and Conditions